TargetRX Received $9.6 Million for a Physicians and Pharmaceutical Community

  • Posted By:
  • 0 Comments... What do you have to say?

TargetRX Received $9.6 Million for a Physicians and Pharmaceutical Community

TargetRX received $9.6 Million in additional funding from Quaker BioVentures, New Enterprise Associates and Domain Associates.

What does TargetRX do?

TargetRX provides services allowing pharmaceutical clients to deploy better sales and marketing campaigns.

VCU says:

TargetRX aims to determine the drivers of physician prescribing behavior which is obviously useful to the pharmaceutical customers.

TargetRx products and services serve to assist pharmaceutical clients to deploy more effective and efficient sales and marketing programs.

On the site it is stated that they have “developed a highly predictive, large-scale normative database of physician attitudes that it uses in combination with its patented proprietary analytic methods to provide pharmaceutical companies with powerful leading indicators of performance.”

The data is used to determine not only how they are doing but how they may perform in the future.

TargetRX has been around for a while, Since 1999, TargetRx has worked with the majority of the top 30 pharmaceutical companies in the U.S.

Take a look at TargetRX Here.




Read more about New Enterprise Associates (NEA) here.

Quaker BioVentures

Domain Associates

See an Error? Contact Us

Comments are closed.

venture capital update google plus page Get updates on Google Plus
venture capital update on facebook Get updates on Facebook
venture capital update on twitter Follow fundings on Twitter
venture capital update on pinterest Visit our Pinterest Page

Subscribe here
TwitterCounter for @longest

Follow here

Venture Capital News


Site Information

    About: I work at Phase One Accelerators and you can find me on and at Brian Longest on LinkedIn.

    Share Us on